Home

Molecular Screening and Therapeutics (MoST) study

MoST was Omico’s pioneering precision oncology study, using comprehensive genomic profiling to identify molecular changes in cancer and help match patients to targeted therapies and clinical trials. While MoST-LLy remains open and is managed by a separate organisation, recruitment has closed to other MoST studies, with follow-up research continuing.

MoST included several screening populations

MoST-LLy – Leukaemia and lymphoma subprogram 

  • For patients with advanced blood cancers without an established therapeutic option.
  • Open for screening – for more information see MoST-LLY at QIMR Berghofer

MoST and AYA-MoST – Pan cancer subprogram 

  • For patients, including Adolescents and Young Adults (AYA), with pathologically-confirmed advanced or metastatic solid cancers of any histological type, either during or after their last line of effective therapy.
  • Closed to new recruitment
  • See CaSP to refer patients for molecular screening

ASPiRATION – Lung cancer subprogram 

  • For adults with newly diagnosed, pathologically-confirmed metastatic non-squamous non-small cell lung cancer (NSCLC), with sufficient and accessible tissue for molecular screening.
  • Closed to new recruitment
  • See CaSP to refer patients for molecular screening

 

MoST clinical trials

A pioneering precision oncology program that helped establish biomarker-led treatment matching in Australia.

Read more about MoST clinical trials

ASPiRATION

An observational cohort study examining the clinical impact of comprehensive genomic profiling. Recruitment has closed.

Read more about ASPiRATION

MoST-LLy

MoST-LLy remains open and is managed by a separate organisation. 

It is a clinical research program offering Australians with blood cancer genomic screening and potential access to precision medicines.

Read more about MoST-LLy

The MoST study had two stages:

Stage 1
We use genomic profiling to analyse the molecular characteristics of a patient’s tumour, we gather as much genetic and clinical information as we can to help us identify specific characteristics about the tumour.

A team of experts review the molecular profile of the tumour with other clinical and patient information. A report is provided to the referring clinician.

Stage 2
Patients identified as possessing any of a range of molecular characteristics (identified during Stage 1) may be eligible to access treatment in a MoST therapeutic study (a clinical trial) or other targeted therapy.

Who could participate in MoST?

Recruitment to all MoST subprograms has now closed, except for MoST-LLy.

The information below describes the eligibility criteria that applied while the study was open.

Pan cancer subprogram:
Patients aged 16 years and older with an advanced and/or metastatic solid or blood cancer with limited treatment options, and who are willing and fit enough to participate in a clinical trial, are eligible.

Lung cancer subprogram:
Patients aged 18 years and older with newly diagnosed metastatic non-squamous non-small cell lung cancer (NSCLC), who have not had any previous treatment for the lung cancer and who are willing and fit enough to participate in a clinical trial, are eligible.

Your treating oncologist will assess your eligibility, complete the MoST referral forms, and provide all relevant information.

What did participation for patients involve?

For patients

  • Discussing the study with the MoST team (either by telephone or face-to-face)
  • Consenting to the access of samples held by pathology centres
  • Consenting to the access of their medical records
  • Donating a blood sample
  • Completing questionnaires
  • Providing optional consent for access to Medicare/PBS data

Interested in knowing more?

Get in touch